$102.76
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Overview
52-week range
$17
$96
100% of range
Avg surprise (last 3)
+9.9%
Avg reaction (last 2)
+1.8%
100% positive
Latest IV / EM
62%
EM ±14.2% · $105 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.85 | $-1.17 | +27.4% | -3.7% | +1.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.97 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.88 | $-0.86 | -2.3% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.82 | $-0.86 | +4.7% | — | +2.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.74 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.51 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-3.78 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-12.73 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.93 | -$0.88 | -5.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $396,000 | $193,000 | $1M | — | $2M | $2M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-47M | — | $-40M | $-35M | $-33M | — | $-30M | $-22M |
| Net income | $-41M | — | $-37M | $-32M | $-30M | — | $-25M | $-18M |
| EPS (diluted) | $-0.85 | — | $-0.97 | $-0.88 | $-0.82 | — | $-0.74 | $-0.51 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $628M | $51M | $56M | $13M | $10M | $23M | $34M | $314M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.12B | $409M | $414M | $264M | $271M | $281M | $287M | $366M |
| Total assets | $1.25B | $531M | $577M | $326M | $349M | $374M | $354M | $369M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $46M | $38M | $31M | $23M | $20M | $22M | $16M | $11M |
| Total equity | $1.20B | $493M | $546M | $303M | $329M | $352M | $338M | $358M |